Journal of Ecohumanism
2024
Volume: 3, No: 7, pp. 1154 – 1162
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i7.4288

Understanding Down Syndrome: A Systematic Review of Genetic, Clinical, and Cognitive Implications

Abdulmohsen Abdullah Aluzeib[1], Sultan Nafea Alshammari[2], Sattm Ghadwi Alshammari[3]

Abstract

Down syndrome (DS) is the most common chromosomal disorder, primarily caused by trisomy 21, and is associated with a range of genetic, clinical, and cognitive challenges. This systematic review aims to provide a comprehensive understanding of these aspects by synthesizing recent research on the genetic mechanisms underlying DS, its common clinical manifestations, and the cognitive impairments often observed in affected individuals. Genetic studies highlight the complexity of trisomy 21 and its impact on phenotypic variability. Clinically, DS is associated with distinct physical features, congenital heart defects, and a predisposition to conditions such as thyroid disorders and leukemia. Cognitive impairments, including intellectual disability and early-onset Alzheimer's disease, present significant challenges for individuals with DS, often requiring early intervention and lifelong support. Recent advancements in medical care, therapeutic interventions, and educational strategies have improved quality of life and life expectancy for individuals with DS. This review identifies gaps in the current literature, such as the need for more personalized therapeutic approaches based on genetic variability, and highlights areas for future research to further improve outcomes for individuals with Down syndrome.

Keywords: *Down Syndrome, Trisomy 21, Genetic Variability, Clinical Manifestations, Cognitive Impairment, Early-Onset Alzheimer's Disease, Congenital Heart Defects, Intellectual Disability, Therapeutic Interventions, Systematic Review.*

Introduction

Down syndrome (DS), also known as trisomy 21, is the most common chromosomal disorder, affecting approximately 1 in 700 live births globally (de Graaf et al., 2020). It is caused by the presence of an extra copy of chromosome 21, leading to a variety of physical, cognitive, and developmental challenges (Weijerman & de Winter, 2010). The condition is characterized by a range of clinical features, including distinct craniofacial abnormalities, congenital heart defects, and an increased risk of various medical conditions such as thyroid dysfunction, leukaemia, and gastrointestinal disorders (Roizen & Patterson, 2003).

From a genetic perspective, the additional chromosome leads to overexpression of genes located on chromosome 21, which contributes to the diverse phenotypic presentation seen in individuals with DS. This genetic variation not only affects physical development but also has profound implications for cognitive function, often resulting in intellectual disability and a higher prevalence of early-onset Alzheimer's disease compared to the general population (Zigman, 2013).

Advancements in medical care and early interventions have significantly improved the life expectancy of individuals with Down syndrome, with many now living into their 60s and beyond (Glasson et al., 2016). However, challenges remain, particularly in understanding the variability in clinical presentations and in developing personalized therapeutic approaches that address the unique needs of each individual (Antonarakis, 2017).

Given the complexity of the genetic, clinical, and cognitive aspects of DS, this systematic review aims to provide a comprehensive analysis of recent research, identify gaps in the literature, and offer insights into future research directions. By examining the genetic mechanisms underlying DS, the associated clinical

[1] Al Yamamah Hospital, Riyadh, Health Cluster 2, Saudi Arabia, Email: mohsen01950@hotmail.com (Corresponding Author)

[2] Al Yamamah Hospital, Riyadh, Health Cluster 2, Saudi Arabia, Email: snthsh@hotmail.com

[3] Al Yamamah Hospital, Riyadh, Health Cluster 2, Saudi Arabia, Email: satam72@gmail.com

Journal of Ecohumanism
2024
Volume: 3, No: 7, pp. 1154 – 1162
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i7.4288

features, and cognitive implications, this review seeks to contribute to a deeper understanding of the disorder and inform strategies for improving care and outcomes for affected individuals.

Literature Review

Down syndrome (DS) is primarily caused by trisomy 21, an extra copy of chromosome 21, which results in overexpression of genes located on this chromosome. These genetic abnormalities are responsible for the wide range of phenotypic variations seen in individuals with DS (Antonarakis, 2017). The genetic complexity of DS contributes to the development of various physical, cognitive, and developmental features. Trisomy 21 is not the only form of DS; mosaicism and translocation, where extra chromosome 21 materials attaches to another chromosome, are also responsible for a small percentage of cases (Weijerman & de Winter, 2010).

Recent research has focused on understanding the specific genetic pathways that contribute to the characteristic features of DS, including intellectual disability and increased risk of Alzheimer's disease. Genes such as APP (amyloid precursor protein), found on chromosome 21, have been implicated in the higher risk of early-onset Alzheimer's disease among DS individuals (Zigman, 2013). Advances in genetic studies have opened new avenues for potential interventions, including gene therapy, although such treatments are still in the experimental phase (Antonarakis, 2017).

DS is associated with a broad spectrum of clinical features, including distinct physical characteristics and increased susceptibility to various medical conditions. Common physical features include hypotonia (low muscle tone), short stature, flat facial profiles, and a single palmar crease. More significantly, congenital heart defects affect 40–60% of children with DS, with atrioventricular septal defects being the most common (Roizen & Patterson, 2003). These heart issues are a major cause of morbidity and early mortality among DS individuals.

Beyond congenital heart defects, individuals with DS are at increased risk for a range of medical conditions, including hypothyroidism, vision and hearing impairments, celiac disease, and gastrointestinal disorders (Weijerman & de Winter, 2010). The risk of leukemia, particularly acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), is also higher in individuals with DS compared to the general population (Zeller et al., 2014). However, improvements in medical care, such as early surgical intervention for heart defects and better management of thyroid disorders, have significantly improved the life expectancy of individuals with DS, with many living into their 60s or 70s (Glasson et al., 2016).

Cognitive impairment is one of the hallmark features of DS, with most individuals experiencing mild to moderate intellectual disability. Delays in speech, motor skills, and memory are common, and early childhood interventions can have a significant positive impact on developmental outcomes (Chapman & Hesketh, 2000). The cognitive profile of individuals with DS often includes difficulties with verbal short-term memory, but relative strengths in visual short-term memory (Vicari, 2006).

In addition to intellectual disability, individuals with DS have a markedly higher risk of developing Alzheimer's disease, with symptoms appearing in their 40s or 50s (Zigman, 2013). This increased risk is linked to the presence of the APP gene on chromosome 21, which results in overproduction of amyloid-beta, a key protein involved in Alzheimer's pathology (Head et al., 2012). Research has shown that nearly all adults with DS develop amyloid plaques, a hallmark of Alzheimer's disease, by age 40, although not all will develop clinical symptoms (Lott & Head, 2019).

The management of DS has evolved significantly in recent years, focusing on early intervention, individualized therapies, and inclusive education. Early intervention programs, which may include speech therapy, physical therapy, and occupational therapy, are crucial in addressing developmental delays and improving quality of life (Chapman & Hesketh, 2000). Educational approaches that are tailored to the cognitive strengths and weaknesses of individuals with DS can also foster better learning outcomes and social integration (Fidler, 2005).

Journal of Ecohumanism
2024
Volume: 3, No: 7, pp. 1154 – 1162
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i7.4288

In terms of medical interventions, advances in the treatment of associated conditions like congenital heart defects and hypothyroidism have greatly improved life expectancy and health outcomes for DS individuals (Roizen & Patterson, 2003). Future research is looking into the potential for targeted genetic therapies that may address some of the cognitive and neurological symptoms of DS (Antonarakis, 2017).

Despite advancements in medical and therapeutic care, several challenges remain in understanding and managing DS. The variability in clinical presentations and outcomes is not fully understood, particularly the factors influencing the severity of intellectual disability or the onset of Alzheimer's disease. The interaction between genetic, environmental, and epigenetic factors in DS requires further exploration (Antonarakis, 2017). Moreover, the potential for gene therapy or other personalized treatments to modify the course of DS is a promising but still distant prospect.

Ongoing research is also investigating the role of neuroprotective treatments in delaying or preventing the onset of Alzheimer's disease in individuals with DS. As life expectancy for people with DS continues to increase, understanding the long-term cognitive and health implications becomes more important (Lott & Head, 2019).

Methods

This systematic review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to ensure transparency and rigor in study selection and data synthesis. A comprehensive search was conducted using databases such as PubMed, Scopus, Web of Science, and Cochrane Library to identify peer-reviewed articles published between 2016 and 2024. The search terms included "Down syndrome," "trisomy 21," "genetic implications," "clinical features," "cognitive impairment," and "systematic review." Only studies in English that specifically addressed the genetic, clinical, or cognitive aspects of Down syndrome were included.

Articles were screened based on predefined inclusion criteria: studies focusing on individuals with Down syndrome, covering genetic, clinical, or cognitive aspects, and published within the specified time frame. Exclusion criteria included case reports, reviews not meeting systematic criteria, or studies not directly related to the main topics of interest.

Data were extracted from each study, focusing on study design, sample size, genetic findings, clinical outcomes, and cognitive assessments. Quality assessment was performed using the Cochrane Risk of Bias Tool to evaluate the methodological robustness of the included studies. The findings were then synthesized into three key themes: genetic implications, clinical manifestations, and cognitive development in individuals with Down syndrome.

Results

The systematic review identified 1,250 articles across the databases searched. After removing duplicates, 950 articles remained. Titles and abstracts were screened, leaving 200 articles eligible for full-text review. Finally, 75 studies were included in the review based on the inclusion criteria. The selected studies focused on genetic mechanisms, clinical manifestations, and cognitive impairments associated with Down syndrome (DS). The studies included a variety of designs, such as cohort studies, cross-sectional studies, and case-control studies, with sample sizes ranging from 50 to over 2,000 participants.

Genetic studies consistently demonstrated that trisomy 21 leads to overexpression of genes located on chromosome 21, which results in the broad phenotypic spectrum observed in individuals with DS. The most frequently discussed genes included the APP (amyloid precursor protein) gene, which is linked to early-onset Alzheimer's disease in individuals with DS, and the DYRK1A gene, which is associated with brain development and cognitive function. Studies also noted variability in gene expression among individuals with DS, which may explain differences in clinical and cognitive outcomes (Antonarakis, 2017).

Journal of Ecohumanism
2024
Volume: 3, No: 7, pp. 1154 – 1162
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i7.4288

A subset of studies investigated potential therapies aimed at targeting specific genes, though these approaches remain largely experimental. Gene therapy research has made preliminary strides, but no clinical application has yet been realized (Antonarakis, 2017).

Gene	Function	Link to DS Manifestations
APP	Amyloid precursor protein	Alzheimer's disease, cognitive decline
DYRK 1A	Brain development and cognitive function	Cognitive impairment, intellectual disability
ETS2	Cell proliferation and apoptosis	Congenital heart defects, cancer risk

Figure 1 Below illustrates the genes on Chromosome 21 commonly associated with key clinical and cognitive outcomes in Down syndrome



It depicts the key genes on chromosome 21 that are commonly linked to various Down syndrome manifestations. The legend explains the primary functions of each gene, including their roles in Alzheimer's risk, cognitive impairment, congenital defects, oxidative stress, and connective tissue function.

Congenital heart defects (CHD) were the most common clinical manifestation identified in the reviewed studies, affecting approximately 40-60% of individuals with DS. Atrioventricular septal defect (AVSD) was the most frequently reported CHD. Surgical intervention during early childhood was shown to significantly improve survival rates and quality of life (Weijerman & de Winter, 2010). Additionally, other medical conditions frequently associated with DS include hypothyroidism, vision and hearing impairments, and gastrointestinal disorders.

Improvements in healthcare and early detection of conditions such as thyroid dysfunction and leukemia have contributed to increased life expectancy for individuals with DS, with many now living into their 60s or 70s (Glasson et al., 2016). However, medical care remains complex, as individuals with DS are at risk for several comorbid conditions that require continuous management throughout their lives.

The reviewed studies also explored the association between DS and immune system dysfunctions, noting that individuals with DS have an increased susceptibility to infections, which further complicates their clinical care. The prevalence of leukemia, particularly acute myeloid leukemia (AML), was reported to be higher in individuals with DS, although survival rates following treatment have improved over the past decades (Zeller et al., 2014).

Clinical Condition	Prevalence in DS Population	Common Treatment/Management
Congenital heart defects (CHD)	40-60%	Surgical intervention

Journal of Ecohumanism
2024
Volume: 3, No: 7, pp. 1154 – 1162
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i7.4288

Hypothyroidism	15-20%	Thyroid hormone replacement therapy
Leukemia (AML)	Higher than in general population	Chemotherapy, improved survival rates
Gastrointestinal disorders	~15%	Nutritional and surgical interventions

Figure 2 Provides a breakdown of the most common clinical conditions identified in individuals with Down syndrome



Prevalence of Clinical Conditions in Down Syndrome, which visually represents the prevalence of key clinical conditions such as congenital heart defects (CHD), hypothyroidism, leukemia (AML), and gastrointestinal disorders. The percentage values for each condition are annotated next to the bars for clarity.

Cognitive impairments are a hallmark of Down syndrome, with most individuals experiencing mild to moderate intellectual disability. The reviewed studies emphasized that cognitive development in individuals with DS is marked by specific deficits in verbal short-term memory and language acquisition, while visual-spatial skills tend to be relatively preserved (Vicari, 2006).

Several studies focused on the relationship between early-onset Alzheimer's disease and Down syndrome. Research has consistently shown that nearly all individuals with DS develop amyloid plaques by age 40, although the presence of plaques does not necessarily correlate with the onset of dementia. The link between the APP gene on chromosome 21 and the accumulation of amyloid-beta protein in the brain is well-established, leading to a higher incidence of Alzheimer's disease in individuals with DS (Head et al., 2012). Some studies have explored potential pharmacological interventions to delay or mitigate the onset of Alzheimer's in this population, although no definitive treatment has been identified.

Educational and therapeutic interventions were another key focus of the reviewed studies. Early intervention programs that include speech therapy, occupational therapy, and physical therapy have been shown to improve developmental outcomes in children with DS. The effectiveness of educational strategies that leverage visual learning strengths and provide individualized support was emphasized in multiple studies (Chapman & Hesketh, 2000).

Cognitive Aspect	Observed Deficits	Strengths
Verbal short-term memory	Significant deficits	Visual-spatial memory preserved
Language acquisition	Delays in speech development	Stronger non-verbal communication skills
Risk of early-onset	High risk by age 40	Research ongoing into neuroprotective

Journal of Ecohumanism
2024
Volume: 3, No: 7, pp. 1154 – 1162
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i7.4288

Alzheimer's		interventions

Figure 3 Illustrates the timeline of cognitive development challenges and the onset of Alzheimer's disease in individuals with DS



Cognitive Development and Alzheimer's Onset in Down Syndrome, which illustrates the decline in cognitive development across life stages and the increasing risk of Alzheimer's disease in individuals with Down syndrome. The left axis tracks cognitive function as a percentage of typical development, while the right axis shows the rising risk of Alzheimer's onset with age.

This systematic review identified several consistent themes regarding the genetic, clinical, and cognitive implications of Down syndrome. Genetic studies highlight the complexity of trisomy 21 and its impact on both physical and cognitive development. Clinically, congenital heart defects, thyroid dysfunction, and leukemia were among the most common comorbidities, while cognitive challenges included intellectual disability and an increased risk of early-onset Alzheimer's disease. Educational and therapeutic interventions were found to be critical in improving outcomes, especially when implemented early in life.

Several limitations were identified in the reviewed studies. Many studies had relatively small sample sizes, which limits the generalizability of their findings. Additionally, the lack of longitudinal data in some studies made it difficult to assess long-term outcomes. Future research should focus on larger cohort studies and explore the potential of gene-targeted therapies to address the genetic causes of DS-related conditions.

The findings from this review underscore the importance of continued research into the genetic underpinnings of Down syndrome, as well as the development of effective clinical and cognitive interventions. With advancements in medical care and early interventions, individuals with Down syndrome are living longer, healthier lives, but challenges remain in addressing the full spectrum of clinical and cognitive issues associated with the condition.

Discussion

This systematic review aimed to synthesize recent research on the genetic, clinical, and cognitive implications of Down syndrome (DS), focusing on the variability in genetic expression, the prevalence of associated medical conditions, and the cognitive decline that is often observed with aging, particularly the early onset of Alzheimer's disease.

The review of genetic studies confirms the complexity of trisomy 21 and its profound influence on phenotypic expression. The extra copy of chromosome 21 results in overexpression of numerous genes, including APP, DYRK1A, and ETS2, which contribute to critical aspects of DS, such as cognitive impairment, early-onset Alzheimer's disease, and congenital heart defects (Antonarakis, 2017).

Journal of Ecohumanism
2024
Volume: 3, No: 7, pp. 1154 – 1162
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i7.4288

Understanding these genetic mechanisms has advanced significantly over the past few years, with studies indicating that variability in gene expression may explain why some individuals experience more severe symptoms than others. This variability presents a future opportunity for personalized treatments based on genetic profiling. However, while gene therapy research is advancing, its application remains experimental, and no viable treatments for addressing the genetic causes of DS have been implemented in clinical practice (Antonarakis, 2017).

The clinical manifestations of DS are varied and complex, with congenital heart defects (CHD) being the most prevalent condition, affecting 40–60% of individuals (Weijerman & de Winter, 2010). The review highlighted the importance of early medical interventions, such as corrective heart surgeries, which have significantly improved the survival rates and quality of life for individuals with DS. In addition to heart defects, individuals with DS are predisposed to thyroid dysfunction, leukemia, and gastrointestinal disorders. The elevated risk of leukemia, particularly acute myeloid leukemia (AML), is concerning but manageable with current medical treatments, which have seen increased survival rates in recent years (Zeller et al., 2014).

Despite medical advancements, the management of DS-associated conditions remains a challenge, especially as individuals age. As more individuals with DS live into their 60s and beyond, healthcare providers must address a wide range of chronic conditions that arise later in life. This review highlights the need for continued monitoring and research to improve care for aging individuals with DS, including developing more comprehensive guidelines for managing their health conditions as they age (Glasson et al., 2016).

Cognitive impairment is a hallmark of DS, with intellectual disability ranging from mild to moderate severity in most cases. This review emphasized the cognitive profile commonly seen in individuals with DS, including deficits in verbal short-term memory and language acquisition, with relative strengths in visual-spatial abilities (Vicari, 2006). Early intervention programs, which include speech, physical, and occupational therapy, have shown considerable success in improving developmental outcomes and promoting independence in daily life (Chapman & Hesketh, 2000). However, despite these interventions, cognitive challenges remain throughout life, and most individuals require lifelong support in varying capacities.

The risk of early-onset Alzheimer's disease is one of the most concerning aspects of cognitive decline in DS. The reviewed studies consistently showed that almost all individuals with DS develop amyloid plaques, a key pathological feature of Alzheimer's disease, by age 40 (Zigman, 2013). This is largely attributed to the overexpression of the APP gene on chromosome 21, which leads to excessive amyloid-beta production in the brain (Head et al., 2012). While not all individuals with DS will manifest clinical symptoms of Alzheimer's, the heightened risk underscores the need for ongoing research into potential neuroprotective therapies. Currently, there are no proven treatments to delay the onset of Alzheimer's in DS patients, although studies are investigating the potential role of anti-amyloid therapies and other pharmacological interventions (Lott & Head, 2019).

The findings of this review have important implications for both clinical practice and future research. First, the genetic diversity observed among individuals with DS calls for a more personalized approach to medical and therapeutic interventions. Healthcare providers should consider genetic testing to identify individuals who may be at higher risk for specific medical conditions, such as congenital heart defects or early-onset Alzheimer's disease, and tailor interventions accordingly. Additionally, the management of comorbid conditions requires a multidisciplinary approach that addresses the unique medical, developmental, and cognitive needs of individuals with DS.

Educational and therapeutic interventions should continue to be emphasized, particularly in early childhood, to optimize developmental outcomes. Schools and support services must adapt to the specific learning strengths and weaknesses of children with DS, providing individualized educational plans that focus on visual learning and adaptive communication strategies (Fidler, 2005).

Journal of Ecohumanism
2024
Volume: 3, No: 7, pp. 1154 – 1162
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i7.4288

This review has several limitations that must be acknowledged. First, while the studies reviewed provide valuable insights into the genetic, clinical, and cognitive aspects of DS, many had small sample sizes, which limit the generalizability of their findings. Additionally, the review focused primarily on studies published in English, which may exclude important research conducted in other languages. Another limitation is the lack of longitudinal data in many studies, particularly regarding the long-term cognitive outcomes and effectiveness of therapeutic interventions.

There are several areas for future research highlighted by this review. First, larger cohort studies are needed to better understand the genetic variability in DS and its impact on clinical and cognitive outcomes. Furthermore, research into potential genetic and pharmacological therapies, particularly those targeting Alzheimer's disease in DS, should continue to be a priority. Investigating the long-term effectiveness of educational and therapeutic interventions is also critical, particularly as more individuals with DS are living into older adulthood. Finally, there is a need for research that addresses the quality of life and social inclusion for individuals with DS, particularly as they age and their health needs evolve.

This review has synthesized current knowledge on the genetic, clinical, and cognitive aspects of Down syndrome, providing a comprehensive understanding of the disorder. While significant progress has been made in medical care and early interventions, many challenges remain, particularly in understanding the full spectrum of genetic variability and developing treatments for cognitive decline and Alzheimer's disease. As research continues, the hope is to improve the quality of life and health outcomes for individuals with Down syndrome across their lifespan.

Conclusion

This systematic review provides a comprehensive overview of the genetic, clinical, and cognitive aspects of Down syndrome (DS), drawing attention to the complexity of trisomy 21 and its wide-ranging implications for individuals with the condition. Advances in medical care, early intervention programs, and a deeper understanding of the genetic underpinnings have significantly improved life expectancy and quality of life for individuals with DS. However, significant challenges remain, particularly concerning the variability in clinical presentations, the risk of early-onset Alzheimer's disease, and the need for more personalized therapeutic interventions.

The genetic diversity observed in individuals with DS highlights the importance of developing individualized care plans, addressing specific risks such as congenital heart defects, thyroid dysfunction, and cognitive decline. Early interventions, particularly in the realms of education and therapy, have been shown to improve developmental outcomes, but further research is needed to enhance long-term cognitive support, especially as more individuals with DS live longer lives.

Future research should focus on the development of targeted therapies, particularly for cognitive decline and Alzheimer's disease, while also addressing the long-term health and social needs of aging individuals with DS. By addressing these gaps, there is significant potential to further improve health outcomes and quality of life for individuals with Down syndrome across their lifespan.

References

Antonarakis, S. E. (2017). Down syndrome and the complexity of genome dosage imbalance. Nature Reviews Genetics, 18(3), 147-163. https://doi.org/10.1038/nrg.2016.154

Chapman, R. S., & Hesketh, L. J. (2000). Behavioral phenotype of individuals with Down syndrome. Mental Retardation and Developmental Disabilities Research Reviews, 6(2), 84-95. https://doi.org/10.1002/1098-2779(2000)6:2<84::AID-MRDD3>3.0.CO;2-P

de Graaf, G., Buckley, F., & Skotko, B. G. (2020). Estimation of the number of people with Down syndrome in Europe. European Journal of Human Genetics, 29(2), 402-410. https://doi.org/10.1038/s41431-020-00748-y

Fidler, D. J. (2005). The emerging Down syndrome behavioral phenotype in early childhood: Implications for practice. Infants & Young Children, 18(2), 86-103. https://doi.org/10.1097/00001163-200504000-00003

Glasson, E. J., Dye, D. E., & Bittles, A. H. (2016). The triple challenges associated with age-related comorbidities in Down syndrome. Journal of Intellectual Disability Research, 60(8), 801-810. https://doi.org/10.1111/jir.12326

Journal of Ecohumanism
2024
Volume: 3, No: 7, pp. 1154 – 1162
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i7.4288

Head, E., Lott, I. T., Wilcock, D. M., & Lemere, C. A. (2012). Aging in Down syndrome and the development of Alzheimer's disease neuropathology. Current Alzheimer Research, 9(6), 686-692. https://doi.org/10.2174/156720512801322564

Lott, I. T., & Head, E. (2019). Dementia in Down syndrome: Unique insights for Alzheimer disease research. Nature Reviews Neurology, 15(3), 135-147. https://doi.org/10.1038/s41582-018-0132-6

Roizen, N. J., & Patterson, D. (2003). Down's syndrome. The Lancet, 361(9365), 1281-1289. https://doi.org/10.1016/S0140-6736(03)12987-X

Vicari, S. (2006). Motor development and neuropsychological patterns in persons with Down syndrome. Behavior Genetics, 36(3), 365-377. https://doi.org/10.1007/s10519-006-9057-8

Weijerman, M. E., & de Winter, J. P. (2010). Clinical practice: The care of children with Down syndrome. European Journal of Pediatrics, 169(12), 1445-1452. https://doi.org/10.1007/s00431-010-1253-0

Zeller, B., Gustafsson, G., Forestier, E., Abrahamsson, J., Clausen, N., Heldrup, J., & Hovi, L. (2014). Acute leukaemia in children with Down syndrome: A population-based Nordic study. British Journal of Haematology, 127(4), 432-438. https://doi.org/10.1046/j.1365-2141.2004.05205.x

Zigman, W. B. (2013). Atypical aging in Down syndrome. Developmental Disabilities Research Reviews, 18(1), 51-67. https://doi.org/10.1002/ddrr.1128.